deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT03611010

Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

Phase II, Dose-ranging Study to Evaluate the Efficacy Dose Response and Pharmacokinetics of Intravenous Atorvastatin in Hypercholesterolemic Patients Previously Controlled With Oral Atorvastatin

Sponsor: Cumberland Pharmaceuticals

Conditions Dyslipidemias Hypercholesterolemia
Interventions Atorvastatin injection
Updated 12 times since 2018 Last updated: Jun 22, 2022 Started: Aug 7, 2018 Primary completion: Feb 17, 2020 Completion: Feb 24, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Dyslipidemias and Hypercholesterolemia and is currently completed. Cumberland Pharmaceuticals leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshotRecruiting~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshotRecruiting~Jan 2019 – ~May 2019 · 4 months · monthly snapshotRecruiting~May 2019 – ~Mar 2020 · 10 months · monthly snapshotRecruiting~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshotActive Not Recruiting~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshotCompleted~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotCompleted~Feb 2021 – ~Apr 2022 · 14 months · monthly snapshotCompleted~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshotCompleted~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Apr 2022 — Sep 2022 [monthly]

    Completed PHASE2

  5. Feb 2021 — Apr 2022 [monthly]

    Completed PHASE2

▶ Show 7 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE2

  2. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. May 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

  5. Jan 2019 — May 2019 [monthly]

    Recruiting PHASE2

  6. Oct 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  7. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

    First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cumberland Pharmaceuticals
Data source: Cumberland Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations